Open Beta
MetriLume

US marketsBBIO

SEC-sourced researchBeta

BBIO

BridgeBio Pharma, Inc.

Company comparison ↗

Data passport

CIK
0001743881
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Nov 19, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 9,303,000.0000 USD; December 2024: 221,902,000.0000 USD; December 2025: 502,076,000.0000 USD502.1M USD0 USD0December 2023December 2024December 2025
BBIO · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20239,303,000.0000Feb 24, 2026
December 2024221,902,000.0000Feb 24, 2026
December 2025502,076,000.0000Feb 24, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025502,076,000.0000-732,938,000.0000-445,910,000.0000936,025,000.00003,012,606,000.0000Feb 24, 2026
December 2024221,902,000.0000-543,347,000.0000-520,726,000.0000919,338,000.00002,376,950,000.0000Feb 24, 2026
December 20239,303,000.0000-653,251,000.0000-527,720,000.0000——Feb 24, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

40/100
Profitability0
Growth100
Balance sheet0
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$502.08MJan 1, 2025 – Dec 31, 2025Feb 24, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$221.9MJan 1, 2024 – Dec 31, 2024Feb 24, 202610-K
Net incomeProfitLoss-$732.94MJan 1, 2025 – Dec 31, 2025Feb 24, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$445.91MJan 1, 2025 – Dec 31, 2025Feb 24, 202610-K
Total assetsAssets$936.03MDec 31, 2025Feb 24, 202610-K
Total liabilitiesLiabilities$3.01BDec 31, 2025Feb 24, 202610-K

New filings

Explore methodology ↗